A phase II trial of the tyrosine kinase inhibitor ponatinib in >400 patients with accelerated-phase chronic myeloid leukaemia (CML), chronic-phase CML and Philadelphia-chromosome-positive acute lymphoblastic leukaemia (ALL) has shown significant results. In patients with chronic-phase CML, >50% experienced a major cytogenetic response and 46% experienced a complete cytogenetic response. In patients with ALL, 41% had a major haematological response and 47% had a major cytogenetic response. These results come as welcome news for these heavily pretreated patients with resistance or unacceptable adverse responses to dasatinib or nilotinib.
References
Cortes, J. E. et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 10.1056/NEJMoa1306494
Rights and permissions
About this article
Cite this article
Ponatinib active in BCR–ABL-positive disease. Nat Rev Clin Oncol 11, 2 (2014). https://doi.org/10.1038/nrclinonc.2013.221
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2013.221